Naoka Murakami, Patrick Mulvaney, Melissa Danesh, Ala Abudayyeh, Adi Diab, Noha Abdel-Wahab, Maen Abdelrahim, Pascale Khairallah, Shayan Shirazian, Aleksandra Kukla, Itunu O Owoyemi, Tarek Alhamad, Samir Husami, Madhav Menon, Andrew Santeusanio, Christopher Blosser, Sandra Carias Zuniga, Maria Jose Soler, Francesc Moreso, Zain Mithani, David Ortiz-Melo, Edgar A Jaimes, Victoria Gutgarts, Erik Lum, Gabriel M Danovitch, Francesca Cardarelli, Reed E Drews, Claude Bassil, Jennifer L Swank, Scott Westphal, Roslyn B Mannon, Keisuke Shirai, Abhijat Kitchlu, Song Ong, Shana M Machado, Suraj S Mothi, Patrick A Ott, Osama Rahma, F Stephen Hodi, Meghan E Sise, Shruti Gupta, David E Leaf, Craig E Devoe, Rimda Wanchoo, Vinay V Nair, Chrysalyne D Schmults, Glenn J Hanna, Ben Sprangers, Leonardo V Riella, Kenar D Jhaveri
Immune checkpoint inhibitors (ICIs) are widely used for various malignancies. However, their safety and efficacy in patients with a kidney transplant have not been defined. To delineate this, we conducted a multicenter retrospective study of 69 patients with a kidney transplant receiving ICIs between January 2010 and May 2020. For safety, we assessed the incidence, timing, and risk factors of acute graft rejection. For efficacy, objective response rate and overall survival were assessed in cutaneous squamous cell carcinoma and melanoma, the most common cancers in our cohort, and compared with stage-matched 23 patients with squamous cell carcinoma and 14 with melanoma with a kidney transplant not receiving ICIs...
December 23, 2020: Kidney International